Revenue: As of FY2025 Q4, the actual value is USD 1.26 B, beating the estimate of USD 1.241 B.<h3>Segment Revenue</h3><ul><li>Total Revenue for Q4 2025: Approximately $1.260 billion, an increase of 13% over Q4 2024.</li><li>U.S. Revenue for Q4 2025: Approximately $892 million, representing growth of 11% over Q4 2024.</li><li>International Revenue for Q4 2025: Approximately $368 million, an increase of 18% over Q4 2024.</li><li>Total Revenue for Fiscal 2025: Approximately $4.662 billion, an increase of 16% over 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Non-GAAP Gross Profit Margin Guidance for 2025: Approximately 61%.</li><li>Non-GAAP Operating Margin Guidance for 2025: 20-21%.</li><li>Dexcom, Inc. has expanded from approximately $250 million to more than $4.6 billion in annual revenue under the leadership of former CEO Kevin Sayer.</li></ul><h3>Cash Flow</h3><ul><li>The reference did not provide specific details on operating cash flow or free cash flow.</li></ul><h3>Unique Metrics</h3><ul><li>Dexcom is launching a completely reimagined Stelo app experience in 2026, with AI-enabled features to personalize insights and enhance user experience, including robust capabilities around food logging like macronutrient information.</li><li>Dexcom has increased product availability with the Dexcom G7 15 Day CGM System, which began shipping to pharmacies in early January 2026.</li></ul><h3>Outlook / Guidance</h3><ul><li>Total Revenue for 2026: Expected to be $5.16 - $5.25 billion, representing growth of approximately 11-13% over 2025.</li><li>Non-GAAP Gross Profit Margin for 2026: Estimated to be approximately 63 – 64%.</li><li>Non-GAAP Operating Margin for 2026: Estimated to be approximately 22 – 23%.</li><li>Dexcom is poised to transform more lives through its glucose biosensing technology in 2026, with continued investments across its portfolio, including the pharmacy launch of Dexcom G7 15 Day and AI-driven enhanced features.</li></ul>

DexCom | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 1.26 B